Outcome of hepatectomy for hepatocellular carcinoma in patients with renal dysfunction  by Toshima, Takeo et al.
ORIGINAL ARTICLE
Outcome of hepatectomy for hepatocellular carcinoma in patients
with renal dysfunction
Takeo Toshima, Ken Shirabe, Shohei Yoshiya, Jun Muto, Toru Ikegami, Tomoharu Yoshizumi & Yoshihiko Maehara
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Abstracthpb_452 317..324
Objectives: There are few reports on the efficacy of hepatectomy for hepatocellular carcinoma (HCC) in
patients with renal dysfunction (RD). This study aimed to clarify the validity of hepatectomy for treating
HCC in RD patients, and to compare postoperative courses in RD and non-RD patients.
Methods: The clinical features of 722 HCC patients who underwent curative hepatectomy between 1986
and 2009 were retrospectively reviewed. Seventeen patients (2.4%) with preoperative serum creatinine
levels of >2.0 mg/dl were defined as the RD group, and, of these, seven who did not receive preoperative
haemodialysis were defined as borderline patients. Clinicopathological characteristics and postoperative
outcomes were compared between the RD group (n = 17) and the non-RD group (n = 705). The
postoperative courses of borderline patients were reviewed in detail.
Results: Overall survival (P = 0.177) and disease-free survival (P = 0.942) after hepatectomy did not differ
significantly between the groups. Incidences of massive ascites (35.3% vs. 14.3%; P = 0.034) and pleural
effusion (52.9% vs. 17.6%; P = 0.001), defined as massive effusion (ME), were significantly higher in the
RD group than in the non-RD group. Hypoalbuminaemia (2.8 g/dl; P = 0.031), heavy blood loss
(1000 ml; P = 0.012) and intraoperative blood transfusion (P = 0.007) were risk factors for ME. Among
the borderline patients, serum creatinine values were not increased immediately after surgery and four
patients underwent haemodialysis.
Conclusions: Preoperative hypoalbuminaemia, heavy blood loss and blood transfusion are independent
risk factors for ME in RD patients. Preoperative improvement of anaemia and reduction of blood loss by
meticulous surgical techniques may prevent ME in RD patients who require hepatectomy for HCC.
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Introduction
Hepatocellular carcinoma (HCC) is a common malignancy
worldwide and its incidence is increasing.1,2 The majority of
asymptomatic HCC patients are diagnosed at an advanced stage;
therefore, their prognosis is not favourable.3–5 The number of
patients with chronic kidney disease who eventually submit to
end-stage renal failure and require haemodialysis is rising in line
with an increase in lifestyle-related diseases such as diabetes and
metabolic syndrome.6 Some reports have demonstrated that the
presence of renal dysfunction (RD) in patients with malignancy
may have a negative prognostic impact, such as an increased risk
for tumour recurrence,7,8 massive ascites as liver dysfunction,9–11
worsening of hepatitis,12,13 and other complications such as surgi-
cal site infections.14,15 Only three studies have demonstrated the
results of hepatectomy in HCC patients with RD.16–18 All of them
reported that liver resection for HCC was justified in selected
patients with end-stage renal failure as a result of improvements
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in techniques and knowledge of RD; however, this has not been
demonstrated in borderline patients with RD in whom haemodi-
alysis is not initiated preoperatively.16–18 Surgeons who are con-
cerned about the postoperative induction of haemodialysis are
sometimes unsure whether hepatectomy should be performed.
The current report describes a retrospective study of patients with
curatively resectable HCC, with and without RD, in whom liver
resection was performed, and compares outcomes in patients with
and without RD to determine whether liver resection for HCC is
justified in the subset of patients with RD. The study also exam-
ined clinical findings in borderline patients with RD who did
not receive preoperative haemodialysis and determined the risk
factors for postoperative complications in these patients.
Materials and methods
Patients and indications for hepatectomy
Between January 1986 and August 2009, a total of 722 consecutive
patients underwent curative hepatectomy for primary HCC at the
Department of Surgery and Science, Kyushu University Hospital,
Fukuoka, Japan. During this period, hepatic resection, as the
therapy of choice for primary HCC, was performed to eradicate
the disease. Of these patients, 17 (2.4%) showed preoperative
serum creatinine (Cre) values >2.0 mg/dl and were classified as
the RD group. The remaining 705 patients were classified as the
non-RD group. Additionally, of the 17 patients in the RD group,
seven patients who did not undergo preoperative haemodialysis
were defined as borderline patients.
Tumour-specific evaluation, including abdominal ultrasonog-
raphy, abdominal and thoracic computed tomography (CT),
hepatic angiography with CT, magnetic resonance imaging of
the abdomen, bone scintigraphy, and determination of alpha-
fetoprotein (AFP) and des-g-carboxy prothrombin (DCP), was
performed in all patients admitted for liver resection. Liver func-
tion was evaluated preoperatively according to the Child–Pugh
system of classification and indocyanine green retention test at
15 min (ICG R15), as reported previously.19 The surgical proce-
dure was selected according to the following criteria: trisegment-
ectomy was performed in patients with an ICG R15 result of
<15%; bisegmentectomy was performed in patients with an ICG
R15 result of 15–25%; monosegmentectomy was performed in
patients with an ICG R15 result of 26–35%, and subsegment-
ectomy was performed in patients with an ICG R15 result of
36–45%. The presence of ascites and an ICG R15 result of >45%
were considered as absolute contraindications for resection.
Operative indications in the RD group did not differ from those in
the non-RD group.
The diagnosis of HCC was confirmed by pathological findings
after hepatectomy. Curative resection was defined as complete
macroscopic and microscopic removal of the tumour, excluding
radiofrequency ablation and ethanol injection therapy. The study
protocol conformed to the ethical guidelines of the 1975 Helsinki
Declaration. Informed consent in writing for participation in this
study was obtained from each patient.
Clinical factors
The clinical factors analysed included: age; sex; hepatitis B surface
antigen (HBs-Ag); hepatitis C virus antibody (HCV-Ab); preop-
erative complete blood count; biochemical analyses [Cre, blood
urea nitrogen (BUN), albumin, total bilirubin (T-bil), prothrom-
bin time (PT), ICG R15]; preoperative tumour markers (serum
AFP and DCP); tumour diameter and number; Child–Pugh class;
tumour stage; pathological findings (tumour differentiation,
microvascular invasion, intrahepatic metastasis, degree of chronic
hepatitis in non-cancerous regions); intraoperative and postop-
erative outcomes (operation time, blood loss, type of resection,
resected liver weight, blood transfusion, hospital stay after hepa-
tectomy, complications), and survival. The size of the largest
tumour was measured at its greatest dimension if the patient had
two or more tumours. Two categories of HCC were distinguished
according to whether the disease manifested as a single tumour or
as multiple tumours. Major hepatectomy was defined as involving
no fewer than three segments. Massive ascites was defined as
ascites sustained until postoperative day 7; pleural effusion was
defined in a similar manner. In addition, massive effusion (ME)
was defined as massive ascites and/or pleural effusion.
Histological examination
All of the resected specimens were cut into serial slices of
5–10 mm in thickness and fixed in 10% formalin. After macro-
scopic examination, the slice with the greatest tumour dimension
was trimmed, embedded in a paraffin block, and cut into 4-mm
microscopic sections. The sections were stained with haematoxy-
lin and eosin. Tumour differentiation, microvascular invasion and
intrahepatic metastasis were examined. Tumour–node–metastasis
(TNM) staging and other pathological findings were defined
according to the Liver Cancer Study Group of Japan.20 The extent
of chronic hepatitis in non-cancerous regions was classified
according to the degree of necroinflammatory activity (graded
from A0 to A4) and the degree of fibrosis (staged from F0 to F4).21
Follow-up and treatment of HCC recurrence
The clinical follow-up of patients who underwent hepatectomy
for HCC was conducted according to a strict protocol that did not
change during the study period. Liver function and renal function
tests were performed every day until 1 week postoperatively and
subsequently bi-weekly during the first month and then monthly
for 6 months. Patients underwent ultrasound scans and enhanced
CT scans at 6-month intervals. Hepatic angiography, bone scin-
tigraphy or a thoracic CT scan was also performed when recur-
rence was suspected. The median follow-up period after initial
hepatectomy was 7.1 years.
Patients with recurrent HCC that could be surgically treated for
a cure underwent resection or ablation of tumours. All patients
who were considered to be unsuitable for surgical treatment
were referred for palliative care by radiotherapy, transarterial
catheter chemoembolization or systemic chemotherapy using
5-fluorouracil and cisplatin.
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Statistical analysis
All statistical analyses were performed using jmp Version 7.01
(SAS Institute, Inc., Cary, NC, USA). Continuous variables with
normal distribution are expressed as the mean  standard devia-
tion (SD); those without normal distribution are expressed as
medians and ranges. These variables were compared with inde-
pendent samples using the non-parametric Wilcoxon test or with
dependent samples using the parametric paired t-test. Categorical
data were compared using Fisher’s test and the chi-squared test.
Logistic regression analysis was performed to identify indepen-
dent risk factors for postoperative complications after hepatec-
tomy. P-values of <0.05 were considered to indicate statistical
significance.
Results
Clinical features of HCC patients with RD
The median age of patients in the RD group was 58 years (range:
31–82 years); 14 of the 17 patients were men. The median value of
serum Cre was 6.9 mg/dl (range: 2.3–12.2 mg/dl) and the most
common aetiology for RD was related to diabetes mellitus (n = 8).
Data for longterm outcomes showed that eight patients had recur-
rences and the median recurrence-free survival period was 18.0
months (range: 5.8–38.5 months). Ten patients died during the
follow-up period; the median length of survival was 42.4 months
(range: 2.6–69.9 months).
Comparison of baseline characteristics
Baseline characteristics including background and laboratory data
for the RD group were compared with those for the non-RD
group (Table 1).
Comparison of pathological parameters of resected
HCC and operative findings
The pathological parameters of resected HCC and operative find-
ings are shown in Table 2.
Comparison of overall and disease-free survival rates
Overall and disease-free survival curves are shown in Fig. 1.
Overall survival rates after hepatectomy in the RD and non-RD
groups, respectively, were 74.1% and 74.6% at 3 years, and 53.3%
and 58.7% at 5 years, and thus did not differ significantly between
the groups (P = 0.177). Disease-free survival rates after hepatec-
tomy in the RD and non-RD groups, respectively, were 45.8% and
43.7% at 3 years, and 34.4% and 29.8% at 5 years, and thus did not
differ significantly between the groups (P = 0.942).
Comparison of postoperative clinical courses
Table 3 shows data for the postoperative clinical course in all
patients; postoperative data for borderline patients are shown in
Table 4. None of the seven patients with preoperative borderline
RD showed an increase in serum Cre values immediately after
surgery and three of these patients did not have haemodialysis;
however, in four patients, haemodialysis was initiated postopera-
tively. The median time from hepatectomy to the initiation of
haemodialysis was 8.5 months (range: 2.5–19.5 months). Of the
two patients who underwent anatomical resection of the liver,
haemodialysis was initiated in one at 19 months postoperatively
and not at all in the other patient. Data for longterm outcomes
showed that five patients remained alive during the follow-up
period with a median survival of 25.2 months (range: 18.9–42.2
months).
Table 1 Baseline characteristics of hepatocellular carcinoma patients with and without renal dysfunction (RD) who underwent liver resection
Variable RD group (n = 17) Non-RD group (n = 705) P-value
Age, years, mean  SD 58  2 62  1 0.024
Gender, male, n (%) 14 (82.4) 560 (79.4) 0.053
HBs-Ag positive, n (%) 3 (17.6) 125 (17.7) 0.814
HCV-Ab positive, n (%) 10 (58.8) 392 (55.6) 0.792
Child–Pugh class, A/B/C, n (%) 10/7/0 (58.8/41.2/0) 564/127/14 (80.0/18.0/2.0) 0.438
Diabetes, n (%) 8 (47.1) 187 (26.5) 0.044
Hypertension, n (%) 10 (58.8) 187 (26.5) 0.010
Alcohol abuse, n (%) 6 (35.3) 345 (48.9) 0.439
Serum Cre, mg/dl, mean  SD 6.9  0.1 0.8  0.1 0.001
Serum BUN, mg/dl, mean  SD 58.8  1.2 14.4  0.2 0.001
Serum albumin, g/dl, mean  SD 3.8  0.1 3.6  0.1 0.023
Serum T-bil, mg/dl, mean  SD 0.4  0.1 0.8  0.1 0.001
PT, %, mean  SD 88.0  0.5 91.8  3.4 0.858
ICG R15, %, mean  SD 10.7  2.3 16.9  0.3 0.004
Platelet count, 104/ml, mean  SD 8.8  2.1 9.2  0.3 0.436
Hb, g/dl, mean  SD 9.4  2.1 13.9  0.3 0.018
SD, standard deviation; HBs-Ag, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; Cre, creatinine; BUN, blood urea nitrogen;
T-bil, total bilirubin; PT, prothrombin time; ICG R15, indocyanine green retention rate at 15 min; Hb, haemoglobin.
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Risk factors related to postoperative ME
Risk factors related to postoperative ME in patients with preop-
erative RD are shown in Table 5.
Discussion
The current study investigated the short- and longterm effects of
hepatectomy in RD patients with HCC. This retrospective study is
inherently disadvantaged by its status as a single-centre, non-
randomized study including a small number of Japanese patients.
However, it represents the first review of clinical findings in bor-
derline patients with serum Cre values of >2.0 mg/dl who did not
undergo preoperative haemodialysis. It also investigated risk
factors related to postoperative complications in RD patients.
Overall and disease-free survival rates did not differ between the
RD and non-RD groups. However, the incidence of ME, defined as
massive ascites and/or pleural effusion, was significantly higher in
the RD group than in the non-RD group, and low serum albumin
values, heavy blood loss and need for intraoperative blood trans-
fusion were identified as risk factors for postoperative ME in
patients with RD.
Data for the borderline patients showed no evidence of an
increase in the initiation of haemodialysis after major surgery or
of worse overall survival. Patients with RD are subject to several
types of risk in major surgery, even without a requirement for
haemodialysis,22 and the most critical issue in curative hepatec-
Table 2 Pathological parameters of resected hepatocellular carcinoma and operative findings in patients with and without renal dysfunction
(RD)
Variable RD group (n = 17) Non-RD group (n = 705) P-value
Tumour size, cm, mean  SD 4.1  0.9 3.9  0.1 0.418
Multiple tumours, n (%) 3 (17.6) 176 (25.0) 0.287
TNM stage, I + II/III + IV, n (%) 7/10 (41.2/58.8) 477/228 (67.7/32.3) 0.080
Differentiation, good + moderate/poor, n (%) 9/8 (52.9/47.1) 474/231 (67.2/32.8) 0.404
Microvascular invasion, n (%) 6 (35.3) 251 (35.6) 0.721
Intrahepatic metastasis, n (%) 3 (35.3) 202 (28.7) 0.310
Serum AFP, ng/ml, median (range) 10 (1.5–42 720) 21 (1.5–693 700) 0.433
Serum DCP, mAU/l, median (range) 30 (2–19 280) 22 (2–318 000) 0.442
Operation time, min, mean  SD 309  29 320  4 0.320
Blood loss, g, mean  SD 905  402 1323  61 0.124
Major hepatectomy (Hr2), n (%) 0 17 (2.4) 0.359
Resected liver weight, g, mean  SD 291  76 288  12 0.450
Blood transfusion, n (%) 10 (58.8) 208 (29.5) 0.014
SD, standard deviation; TNM, tumour–node–metastasis; AFP, alpha-fetoprotein; DCP, des-g-carboxyl prothrombin; Hr2, hepatic resection of two
segments.
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Figure 1 (a) Overall survival rates in renal dysfunction (RD) (n = 17) and non-RD (n = 705) patients with hepatocellular carcinoma (HCC).
Overall survival rates in the RD and non-RD groups, respectively, were 74.1% and 74.6% at 3 years, and 53.3% and 58.7% at 5 years
(P = 0.177). (b) Recurrence-free survival rates in RD (n = 17) and non-RD (n = 705) patients with HCC. Recurrence-free survival rates in the
RD and non-RD groups, respectively, were 45.8% and 43.7% at 3 years, and 34.4% and 29.8% at 5 years (P = 0.942)
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tomy in RD patients with HCC is that the procedure is performed
safely in order to prevent the deterioration of renal function and
avoid the need for haemodialysis. According to the Renal Data
Registry Committee of the Japanese Society for Dialysis Therapy,
a survey of over one million Japanese patients found that the
mean age of new patients on dialysis was 67.2 years23 and the time
from first diagnosis of RD to haemodialysis therapy was reported
as in the range of 14.2–27.9 months.24–26 In the present report, four
of seven borderline patients underwent haemodialysis postopera-
tively. Their mean age was 66.1 years (range: 59–72 years) and the
mean time from first diagnosis of RD to haemodialysis therapy
was 28.0 months (range: 14.0–55.5 months). These data suggest
that hepatectomy did not strongly affect the issue of whether or
not postoperative haemodialysis was initiated in borderline
patients.23–26 In terms of prognosis, RD is known to represent a
severe risk factor for cardiovascular dysfunction and cardiorenal
anaemia syndrome,27 and 5-year survival in RD patients who do
not undergo major surgery has been reported as 60.1%.23 In the
present study, the overall survival rate after hepatectomy was
53.3% at 5 years in RD patients. Indeed, there was no strong
evidence that hepatectomy resulted in the deterioration of renal
function and survival rates and it did not increase the initiation of
haemodialysis in borderline RD patients after surgery for HCC.
Cardiorenal anaemia syndrome is the main cause of deterio-
ration in postoperative cardiovascular dysfunction and often
results in other postoperative complications.27 In this syndrome,
activation of the renin–angiotensin–aldosterone system, imbal-
ance of reactive oxygen species, and irritation of the sympathetic
nervous system result in the acceleration of coronary sclerosis,
impairment of cardiac microcirculation, and hypertension.28
Ohno et al. demonstrated that onset of sodium retention is
strongly related to a critical threshold of hepatic function after
hepatectomy in a rodent model.29 The underlying mechanisms
of ME after surgery remain unclear. One of the mechanisms of
ME is an impaired haemodynamic state postoperatively.30,31 A
hypervolemic state exists in patients after hepatectomy, caused
by intraoperative excess infusion or return from the ‘third space’,
even in patients with normal renal function. Fluid in the peri-
toneal cavity and peripheral vasodilatation then contribute to a
decreased effective blood volume, which further compromises
renal blood volume and the hypervolemic state.32,33 In patients
with RD who tend to be in a hypervolemic state, these mecha-
nisms are likely to aggravate or at least maintain ME develop-
ment and sustain the vicious cycle that causes ME. Activation
of vasoconstrictor systems triggered by liver dysfunction or
inflammatory cytokines released from leukocytes may at least in
Table 3 Postoperative clinical course in patients with hepatocellular carcinoma with and without renal dysfunction (RD)
Variable RD group (n = 17) Non-RD group (n = 705) P-value
Hospital stay, days, mean  SD 41.0  8.1 28.4  1.2 0.026
Complications, n (%) 11 (64.7) 319 (45.2) 0.268
SSI, n (%) 3 (17.6) 80 (11.3) 0.450
Massive ascites, n (%) 6 (35.3) 101 (14.3) 0.034
Pleural effusion, n (%) 9 (52.9) 124 (17.6) 0.001
Postoperative bleeding, n (%) 0 14 (2.0) 0.412
Bile leakage, n (%) 1 (5.8) 36 (5.1) 0.888
Gastrointestinal bleeding, n (%) 0 17 (2.4) 0.365
Liver failure, n (%) 2 (11.8) 23 (3.3) 0.131
SD, standard deviation; SSI, surgical site infection.
Table 4 Characteristics of patients with borderline renal dysfunction preoperatively (n = 7)
Case Age,
years
Gender Aetiology Surgical
method
Serum Cre, mg/dla Duration
from FD to
Hx, months
Duration from
Hx to HI, months
Survival
(months after Hx)
1 82 M HT, RS Partial 2.33/1.55/1.87/1.93/2.12 120 (–) Alive (18.9)
2 61 M DM Partial 3.01/2.11/2.03/2.26/2.89 36 (–) Dead (13.2)
3 58 M DM Seg 3.02/3.05/3.03/3.18/3.81 36 19 Alive (19.9)
4 72 M DM Partial 3.39/5.06/3.91/4.51/4.88 12 2 Alive (42.2)
6 57 M DM Lobe 5.62/5.91/5.87/5.47/5.98 24 (–) Dead (22.0)
7 67 M DM Partial 5.76/6.02/5.99/5.78/8.76 6 8 Alive (19.1)
10 65 F HT Partial 7.28/3.69/6.81/6.73/7.44 24 5 Alive (25.8)
aCreatinine values are: preoperative/1 week postoperatively/2 weeks postoperatively/1 month postoperatively/1 years postoperatively.
Cre, creatinine; FD, first diagnosis of renal dysfunction; Hx, hepatectomy; HI, haemodialysis induction; M, male; F, female; HT, hypertension;
RS, renal sclerosis; DM, diabetes mellitus; Partial, partial hepatectomy; Seg, segmentectomy; Lobe, lobectomy.
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part induce the development of peripheral vasodilatation and
impaired effective blood volume.34,35
Ishizawa et al.36 demonstrated that large blood loss and low
platelet count are independent risk factors for massive ascites after
hepatectomy and discussed how to manage insufficient urinary
output indicating RD caused by portal hypertension in the early
postoperative period. Their findings are consistent with those of
the present study; in fact, large blood loss and hypoalbuminaemia
indicating liver dysfunction were independent risk factors for ME
in the present study and these results do not contradict the finding
of elevated portal hypertension after hepatectomy. It is clear that
liver dysfunction causes an increase in portal hypertension that
exists prior to hepatectomy.37,38 Some studies have reported
that virus titres such as that for HCV decreased in patients after
dialysis.39,40 These data indicated that improvements in liver
function in RD patients compared with those in non-RD patients
may be affected by the reduction of HCV load by dialysis;
however, any direct cause–effect relationship between a reduction
in HCV titre and dialysis remains unknown.
Some studies on attempts to treat cardiorenal anaemia syn-
drome have reported that the administration of erythropoietin
often improves renal anaemia, as well as renal function and sur-
vival after the initiation of haemodialysis.41–43 Previous reports16–18
have demonstrated the effects of hepatectomy in RD patients
receiving haemodialysis and have concluded that careful operative
techniques and perioperative care are crucial to achieving lower
morbidity and mortality in HCC patients with end-stage renal
failure; however, it is not clear how RD patients with HCC who
require hepatectomy should be managed. The preoperative
administration of erythropoietin in RD patients may be very
important for preventing renal anaemia and postoperative
complications such as ME, but further data are required to
confirm the efficacy of erythropoietin in improving postoperative
outcome.41–44
Table 5 Univariate analysis for risk factors related to postoperative massive effusion (ME) in patients with renal dysfunction (n = 17)
Variable Non-ME (n = 11) ME (n = 6) P-value
Age, years, mean  SD 57  4 58  6 0.947
Gender, male, n (%) 1 (0.9) 2 (33.3) 0.220
HBs-Ag positive, n (%) 4 (36.4) 0 0.086
HCV-Ab positive, n (%) 5 (45.5) 5 (83.3) 0.116
Child–Pugh class, A/B + C, n (%) 9/2 (81.8/18.2) 4/2 (66.7/33.3) 0.488
Diabetes, n (%) 5 (45.5) 3 (50.0) 0.858
Hypertension, n (%) 5 (45.5) 5 (83.3) 0.116
Alcohol abuse, n (%) 4 (36.4) 1 (16.7) 0.380
Serum albumin 2.8 g/dl, n (%) 0 2 (33.3) 0.031
Serum T-bil, mg/dl, mean  SD 0.4  0.0 0.3  0.1 0.072
PT, %, mean  SD 92  5 91  7 0.910
ICG R15, %, mean  SD 11.4  2.0 9.1  2.9 0.531
Platelet count, 104/ml, mean  SD 17.5  3.3 14.4  4.4 0.578
Hb, g/dl, mean  SD 9.3  0.6 9.7  0.8 0.653
Tumour size, cm, mean  SD 3.9  0.9 3.6  1.0 0.855
Multiple tumours, n (%) 2 (18.2) 3 (50.0) 0.121
TNM stage, I + II/III + IV, n (%) 6/5 (54.5/45.5) 2/4 (33.3/66.7) 0.531
Tumour differentiation, good + moderate/poor, n (%) 6/5 (54.5/45.5) 4/2 (66.7/33.3) 0.769
Microvascular invasion, n (%) 2 (18.2) 2 (33.3) 0.531
Intrahepatic metastasis, n (%) 2 (18.2) 3 (50.0) 0.181
Serum AFP, ng/ml, mean  SD 4761  3171 356  4294 0.422
Serum DCP, mAU/l, mean  SD 3470  1647 134  2127 0.235
Operation time, min, mean  SD 281  35 353  47 0.239
Blood loss 1000 ml, n (%) 1 (0.9) 4 (66.7) 0.012
Major hepatectomy (Hr2), n (%) 2 (18.2) 2 (33.3) 0.488
Resected liver weight, g, mean  SD 256  115 313  156 0.782
Blood transfusion, n (%) 1 (0.9) 5 (83.3) 0.007
SD, standard deviation; HBs-Ag, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; T-bil, total bilirubin, PT, prothrombin time;
ICG R15, indocyanine green retention rate at 15 min; Hb, haemoglobin; TNM, tumour–node–metastasis; AFP, alpha-fetoprotein;
DCP, des-g-carboxyl prothrombin; Hr2, hepatic resection of two segments.
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In conclusion, RD patients with HCC experience a higher
frequency of postoperative complications such as ME. Hypoal-
buminaemia, massive blood loss and a high frequency of intraop-
erative blood transfusion are independent risk factors for ME,
defined as massive ascites and/or pleural effusion, in RD patients
after hepatectomy. Although it may be possible to safely manage
ME that is mainly caused by renal anaemia, step-by-step trials are
essential to improve postoperative outcomes.
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